An overview on the use of TNF-α: Our experience with regional administration and developments towards new opportunities for systemic application

Anticancer Research

Volumn 20, Issue 5 B, 2000, Pages 3467-3474

  Van Der Veen, A H ^a   Ten Hagen, T L M ^a   De Wilt, J H W ^a   Van Ijken, M G A ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer treatment; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; LIPOSOME; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG RESEARCH; HUMAN; LIMB PERFUSION; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS; HUMANS; LIPOSOMES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033636118     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. The therapeutic value of the mixed toxins of the streptococcus of erysipelas and bacillus prodigious in the treatment of inoperable malignant tumors
2. An endotoxin-induced serum factor that causes necrosis of tumors
3. Dual role of tumor necrosis factor-alpha in angiogenesis
4. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies
5. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin
6. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism
7. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study
8. Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies
9. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites
10. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
11. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study
12. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
13. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
14. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas
15. In vivo isolated kidney perfusion with TNF-αlpha in tumour bearing rats
16. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat
17. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: A new anti-tumour approach
18. Syvnergistic antitumor effects of tumor I necrosis factor and gamma-interferon on human colon carcinoma cell lines
19. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells
20. Synergistic cytotoxicity of recombinant human TNF and various anticancer drugs
21. Augmentation of the radiation-induced antiproliferative effect in combined use of a derivative of nitrosourea, ACNU, with recombinant human tumor necrosis factor
22. Tumor necrosis factor activities and cancer therapy - A perspective
23. Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats
24. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
25. Synergistic effects of TNF-αlpha and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathological, immunohistochemical and electron microscopical study
26. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
27. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature
28. Delivery of molecular medicine to solid tumors
29. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1
30. Toxic effect of tumor necrosis factor on tumor vasculature in mice
31. Recombinant human tumor necrosis factor-alpha: Thrombus formation is a cause of anti- tumor activity
32. Tumor necrosis factor/cachectin-induced intravascalar fibrin formation in meth A fibrosarcomas
33. In vivo targets of recombinant human tumour necrosis factor-alpha: Blood flow, oxygen consumption and growth of isotransplanted rat tumours
34. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha
35. Complete response of melanomain-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: A clinical and histopathological study of the delayed-type reaction pattern
36. Reduction of interstitial fluid pressure after TNF-αlpha treatment of three human melanoma xenografts
37. Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice
38. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms
39. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan
40. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules
41. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)
42. Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats
43. Evidence for the involvement of endothelial cell integrin alpha Vbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma
44. In vivo anti-tumour activity of recombinant human and mutine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma
45. Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer
46. Anti-tumor activity of recombinant mouse tumor necrosis factor (INF) on colon cancer in rats is promoted by recombinant rat interferon gamma; toxicity is reduced by indomethacin
47. Toxicity and anti-tumor activity of interferon gamma alone and in combination with TNF alpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats
48. Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor- alpha
49. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models
50. Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: Tumor size influences the response to therapy
51. Biologic therapy with TNF: Preclinical studies
52. Mechanism of synergistic cytotoxic effect between tumor necrosis factor and hyperthermia
53. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer
54. The efficacy of combined treatment with recombinant human tumor necrosis factor-alpha and 5-fluorouracil is dependent on the development of capillaries in tumor
55. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients
56. Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma
57. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma
58. A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma
59. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer
60. A pilot study of recombinant human TNF and interferon-gamma in four patients with refractory AML
61. Intralesional recombinant tumor necrosis factor-alpha for AIDS- associated Kaposi's sarcoma: A randomized, double-blind trial
62. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): A phase one study
63. Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases
64. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit
65. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics
66. Regional therapy of melanoma
67. Treatment of melanoma in-transit metastases confined to the limb
68. Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas
69. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor
70. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases
71. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma
72. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
73. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis
74. Use of tumor necrosis factor in isolated hepatic perfusion
75. Isolated hepatic perfusion in the pig with TNF-αlpha with and without melphalan
76. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: Experimental studies in pigs and phase I data from humans
77. Portal infusion of tumor necrosis factor increases mortality in rats
78. Liver and tumour tissue concentrations of TNF-αlpha in cancer patients treated with TNF-αlpha and melphalan by isolated liver perfusion
79. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1cells
80. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo
81. A YIGSR-containing novel mutein without the detrimental effect of human TNF-alpha of enhancing experimental pulmonary metastasis
82. Overcoming the metastasis-enhancing potential of human tumor necrosis factor alpha by introducing the cell-adhesive Arg-Gly-Asp sequence
83. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice
84. Novel mutein of tumor necrosis factor alpha (F4614) with reduced hypotensive effect
85. New TNF-αlpha analogues: A powerful but less toxic biological tool against tumours
86. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
87. Transport of molecules in the tumor interstitium: A review
88. Barriers to drug delivery in solid tumors
89. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
90. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice
91. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes
92. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
93. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
94. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
95. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid
96. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
97. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy
98. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
99. Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines
100. Liver metastases from colorectal cancer: Drug delivery with liposome-encapsulated doxorubicin
101. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy
102. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
103. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma
104. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats
105. Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies
106. Cytotoxic potential of liposomes containing tumor necrosis factor-alpha against sensitive and resistant target cells
107. Preparation and characterization of liposomal-lipophilic tumor necrosis factor
108. Response of multicellular tumor spheroids to liposomes containing TNF-αlpha
109. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-alpha, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model
110. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-αlpha show improved pharmacokinetics and biological activity and reduced toxicity in mice
111. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes
112. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: Immunomodulatory and anti-tumor activity in mice
113. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats
114. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
115. Treatment of the BN175 extremity soft tissue sarcoma in brown norway rats with TNF-alpha cytotoxic agents
116. A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth liposome encapsulated tumor necrosis factor-alpha and cytotoxic agents